What is the clinical evidence from this study?

Population: Acute coronary syndromes. Intervention: Ticagrelor vs. Clopidogrel. Primary outcome: Incremental cost per QALY gained ($9,745 per QALY gained).

What question did this study set out to answer?

To assess the cost-effectiveness of ticagrelor compared with clopidogrel in patients with acute coronary syndromes from the perspective of the Canadian publicly funded healthcare system.

January 1, 2014ClinicoEconomics and Outcomes ResearchOpen Access

Cost-effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes in Canada

View Full Paper

Ask AI

Bookmark

Key result

Ticagrelor was a cost-effective option compared with clopidogrel for ACS patients in Canada, with an incremental cost of $9,745 per QALY gained.

Why the study?

Is ticagrelor cost-effective compared to clopidogrel in patients with acute coronary syndromes in Canada?

Key Points

To assess the cost-effectiveness of ticagrelor compared with clopidogrel in patients with acute coronary syndromes from the perspective of the Canadian publicly funded healthcare system.
Developed a two-part health economic model combining a 1-year decision tree and a lifetime Markov model.
Extracted clinical events, patient utilities, and healthcare resource utilization from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Applied Canadian-specific unit costs and transition probabilities from published literature, evaluating model uncertainty through univariate and probabilistic sensitivity analyses.
Base case lifetime analysis found ticagrelor generated 0.097 additional life years and 0.084 additional quality-adjusted life years (QALYs) per patient compared with generic clopidogrel.
The incremental cost-effectiveness ratio for ticagrelor was $9,745 Canadian dollars per QALY gained.
Probabilistic sensitivity analysis demonstrated a 93% probability of the incremental cost falling below $20,000 per QALY and a 99% probability of falling below $30,000 per QALY.

Structured PICO

Is ticagrelor cost-effective compared to clopidogrel in patients with acute coronary syndromes in Canada?

Population

Cost-effectiveness model of patients with acute coronary syndromes in Canada based on data from the PLATO trial.

Intervention

Ticagrelor

Comparator

Clopidogrel (assuming generic cost)

Outcome

Incremental cost per quality-adjusted life year (QALY) gained

Main Result

Effect estimate: $9,745 per QALY gained

Ticagrelor is a cost-effective treatment option compared to generic clopidogrel for patients with acute coronary syndromes in the Canadian healthcare system.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Supports ticagrelor reimbursement in Canadian ACS; extends PLATO trial with lifetime economic modeling.

Cite This Study

Grima et al. (2014) studied Acute coronary syndromes. Ticagrelor vs. Clopidogrel was evaluated on Incremental cost per QALY gained ($9,745 per QALY gained). Ticagrelor was a cost-effective option compared with clopidogrel for ACS patients in Canada, with an incremental cost of $9,745 per QALY gained.

synapsesocial.com/papers/6aa01972fb5e17fb76d56140 https://doi.org/10.2147/ceor.s51052

View Full Paper

Ask AI

Bookmark

Cost-effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes in Canada

Key Points

Structured PICO

Main Result

Discussion

Implication

Cite This Study

Cost-effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes in Canada

Key Points

Structured PICO

Main Result

Discussion

Implication

Cite This Study

Also Consider

Also Consider